Curman D, Cinel B, Williams D E, Rundle N, Block W D, Goodarzi A A, Hutchins J R, Clarke P R, Zhou B B, Lees-Miller S P, Andersen R J, Roberge M
Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, British Columbia, V6T 1Z3, Canada.
J Biol Chem. 2001 May 25;276(21):17914-9. doi: 10.1074/jbc.M100728200. Epub 2001 Mar 7.
Cells can respond to DNA damage by activating checkpoints that delay cell cycle progression and allow time for DNA repair. Chemical inhibitors of the G(2) phase DNA damage checkpoint may be used as tools to understand better how the checkpoint is regulated and may be used to sensitize cancer cells to DNA-damaging therapies. However, few inhibitors are known. We used a cell-based assay to screen natural extracts for G(2) checkpoint inhibitors and identified debromohymenialdisine (DBH) from a marine sponge. DBH is distinct structurally from previously known G(2) checkpoint inhibitors. It inhibited the G(2) checkpoint with an IC(50) of 8 micrometer and showed moderate cytotoxicity (IC(50) = 25 micrometer) toward MCF-7 cells. DBH inhibited the checkpoint kinases Chk1 (IC(50) = 3 micrometer) and Chk2 (IC(50) = 3.5 micrometer) but not ataxia-telangiectasia mutated (ATM), ATM-Rad3-related protein, or DNA-dependent protein kinase in vitro, indicating that it blocks two major branches of the checkpoint pathway downstream of ATM. It did not cause the activation or inhibition of different signal transduction proteins, as determined by mobility shift analysis in Western blots, suggesting that it inhibits a narrow range of protein kinases in vivo.
细胞可通过激活检查点来应对DNA损伤,这些检查点会延迟细胞周期进程,为DNA修复留出时间。G(2)期DNA损伤检查点的化学抑制剂可作为工具,用于更好地理解该检查点的调控方式,并可用于使癌细胞对DNA损伤疗法敏感。然而,已知的抑制剂很少。我们使用基于细胞的检测方法筛选天然提取物中的G(2)检查点抑制剂,并从一种海洋海绵中鉴定出脱溴膜盘藻素(DBH)。DBH在结构上与先前已知的G(2)检查点抑制剂不同。它以8微米的半数抑制浓度(IC(50))抑制G(2)检查点,并对MCF-7细胞表现出中等细胞毒性(IC(50)=25微米)。DBH在体外抑制检查点激酶Chk1(IC(50)=3微米)和Chk2(IC(50)=3.5微米),但不抑制共济失调毛细血管扩张症突变蛋白(ATM)、ATM-Rad3相关蛋白或DNA依赖性蛋白激酶,表明它在ATM下游阻断检查点途径的两个主要分支。如通过蛋白质印迹中的迁移率变动分析所确定的,它不会引起不同信号转导蛋白的激活或抑制,这表明它在体内抑制的蛋白激酶范围较窄。